Mohd Wasiullah,
Piyush Yadav,
Harsh Sahu,
Satish kumar Yadav,
Vinay Kumar Deepak,
- Principal Department of Pharmacy, Prasad Institute of Technology, Jaunpur Uttar Pradesh India
- Academic Head Department of Pharmacy, Prasad Institute of Technology, Jaunpur Uttar Pradesh India
- Research Scholar Department of Pharmacy, Prasad Institute of Technology, Jaunpur Uttar Pradesh India
- Associate professor Department of Pharmacy, Prasad Institute of Technology, Jaunpur Uttar Pradesh India
- Associate Professor Department of Pharmacy, Prasad Institute of Technology, Jaunpur Uttar Pradesh India
Abstract
Currently, India’s Directly Observed Treatment Short Course (DOTS) program is the world’s largest and fastest-growing initiative for treating medical patients, second only in terms of population coverage. The main obstacles to TB control in India are inadequate primary healthcare in rural regions of many states, unregulated private treatments resulting in extensive misuse of first- and second-line TB medications, the spread of HIV, a lack of political commitment, and, most importantly, corrupt administration. Tuberculosis (TB) is an airborne disease caused by bacteria from the Mycobacterium tuberculosis complex. tuberculosis is predominantly a lung infection, but it may infect nearly any area of the body. A M. tuberculosis infection can progress from a latent condition, where the bacteria are contained inside granulomas, to a contagious stage, where the patient exhibits symptoms such as fever, chills, coughing, and weight loss. Contagious TB is limited to active pulmonary cases. Drug-resistant tuberculosis (TB) poses a significant challenge in numerous contexts, and TB continues to be a major cause of illness and death in many low- and middle-income countries.
Keywords: Directly Observed Treatment Short Course (DOTS), tuberculosis (TB), drug-resistant TB, first- and second-line TB medications, low- and middle-income nations, active pulmonary TB
[This article belongs to Research & Reviews : A Journal of Immunology(rrjoi)]
References
1. Terracciano E, Amadori F, Zaratti L, Franco E. Tuberculosis: an ever present disease but difficult to prevent. Igiene e sanita pubblica. 2020 Jan 1;76(1):59-66. 2. Mbuh TP, Ane-Anyangwe I, Adeline W, Thumamo Pokam BD, Meriki HD, Mbacham WF. Bacteriologically confirmed extra pulmonary tuberculosis and treatment outcome of patients consulted and treated under program conditions in the littoral region of Cameroon. BMC Pulmonary Medicine. 2019 Dec; 19:1-7. 3. Mathiasen VD, Andersen PH, Johansen IS, Lillebaek T, Wejse C. Clinical features of tuberculous lymphadenitis in a low-incidence country. International Journal of Infectious Diseases. 2020 Sep 1; 98:366-71. 4. Pan Z, Zhang J, Bu Q, He H, Bai L, Yang J, Liu Q, Lyu J. The gap between global tuberculosis incidence and the first milestone of the WHO end tuberculosis strategy: an analysis based on the global burden of disease 2017 database. Infection and Drug Resistance. 2020 May 4:1281-6. 5. Boudville DA, Joshi R, Rijkers GT. Migration and tuberculosis in Europe. Journal of clinical tuberculosis and other mycobacterial diseases. 2020 Feb 1; 18:100143. 6. Cui Y, Shen H, Wang F, Wen H, Zeng Z, Wang Y, Yu C. A long-term trend study of tuberculosis incidence in China, India and United States 1992–2017: a joinpoint and age–period–cohort analysis. International journal of environmental research and public health. 2020 May;17(9):3334. 7. Kuwabara K. Anti-tuberculosis chemotherapy and management of adverse reactions. Nihon rinsho. Japanese Journal of Clinical Medicine. 2011 Aug 1;69(8):1389-93. 8. Metushi I, Uetrecht J, Phillips E. Mechanism of isoniazid‐induced hepatotoxicity: then and now. British journal of clinical pharmacology. 2016 Jun;81(6):1030-6. 9. Chaulk CP, Moore-Rice K, Rizzo R, Chaisson RE. Eleven years of community-based directly observed therapy for tuberculosis. Jama. 1995 Sep 27;274(12):945-51. 10. Weis SE, Slocum PC, Blais FX, King B, Nunn M, Matney GB, Gomez E, Foresman BH. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. New England journal of medicine. 1994 Apr 28;330(17):1179-84. 11. Scriba TJ, Nemes E. Protection against tuberculosis by mucosal BCG administration. Nature Medicine. 2019 Feb;25(2):199-201. 12. Hirsh AE, Tsolaki AG, DeRiemer K, Feldman MW, Small PM. Stable association between strains of Mycobacterium tuberculosis and their human host populations. Proceedings of the National Academy of Sciences. 2004 Apr 6;101(14):4871-6. 13. Rothschild BM, Martin LD, Lev G, Bercovier H, Bar-Gal GK, Greenblatt C, Donoghue H, Spigelman M, Brittain D. Mycobacterium tuberculosis complex DNA from an extinct bison dated 17,000 years before the present. Clinical Infectious Diseases. 2001 Aug 1;33(3):305-11.
Research & Reviews : A Journal of Immunology
| Volume | 14 |
| Issue | 02 |
| Received | May 29, 2024 |
| Accepted | July 19, 2024 |
| Published | August 16, 2024 |